These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 30774763)
1. Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone. Tixier F; Um H; Bermudez D; Iyer A; Apte A; Graham MS; Nevel KS; Deasy JO; Young RJ; Veeraraghavan H Oncotarget; 2019 Jan; 10(6):660-672. PubMed ID: 30774763 [TBL] [Abstract][Full Text] [Related]
2. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma. Xi YB; Guo F; Xu ZL; Li C; Wei W; Tian P; Liu TT; Liu L; Chen G; Ye J; Cheng G; Cui LB; Zhang HJ; Qin W; Yin H J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163 [TBL] [Abstract][Full Text] [Related]
3. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication. Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219 [TBL] [Abstract][Full Text] [Related]
4. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study. Li ZC; Bai H; Sun Q; Li Q; Liu L; Zou Y; Chen Y; Liang C; Zheng H Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594 [TBL] [Abstract][Full Text] [Related]
5. Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma. Lu Y; Patel M; Natarajan K; Ughratdar I; Sanghera P; Jena R; Watts C; Sawlani V Magn Reson Imaging; 2020 Dec; 74():161-170. PubMed ID: 32980505 [TBL] [Abstract][Full Text] [Related]
6. Improving MGMT methylation status prediction of glioblastoma through optimizing radiomics features using genetic algorithm-based machine learning approach. Do DT; Yang MR; Lam LHT; Le NQK; Wu YW Sci Rep; 2022 Aug; 12(1):13412. PubMed ID: 35927323 [TBL] [Abstract][Full Text] [Related]
7. Radiomics Analysis Based on Magnetic Resonance Imaging for Preoperative Overall Survival Prediction in Isocitrate Dehydrogenase Wild-Type Glioblastoma. Wang S; Xiao F; Sun W; Yang C; Ma C; Huang Y; Xu D; Li L; Chen J; Li H; Xu H Front Neurosci; 2021; 15():791776. PubMed ID: 35153659 [TBL] [Abstract][Full Text] [Related]
8. Prediction of MGMT Status for Glioblastoma Patients Using Radiomics Feature Extraction From Qian J; Herman MG; Brinkmann DH; Laack NN; Kemp BJ; Hunt CH; Lowe V; Pafundi DH Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1339-1346. PubMed ID: 32634544 [TBL] [Abstract][Full Text] [Related]
9. Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma. Sasaki T; Kinoshita M; Fujita K; Fukai J; Hayashi N; Uematsu Y; Okita Y; Nonaka M; Moriuchi S; Uda T; Tsuyuguchi N; Arita H; Mori K; Ishibashi K; Takano K; Nishida N; Shofuda T; Yoshioka E; Kanematsu D; Kodama Y; Mano M; Nakao N; Kanemura Y Sci Rep; 2019 Oct; 9(1):14435. PubMed ID: 31594994 [TBL] [Abstract][Full Text] [Related]
10. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Shu C; Wang Q; Yan X; Wang J Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy. Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791 [TBL] [Abstract][Full Text] [Related]
12. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas. Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598 [TBL] [Abstract][Full Text] [Related]
13. Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. Vils A; Bogowicz M; Tanadini-Lang S; Vuong D; Saltybaeva N; Kraft J; Wirsching HG; Gramatzki D; Wick W; Rushing E; Reifenberger G; Guckenberger M; Weller M; Andratschke N Front Oncol; 2021; 11():636672. PubMed ID: 33937035 [TBL] [Abstract][Full Text] [Related]
14. Radiomics Profiling Identifies the Incremental Value of MRI Features beyond Key Molecular Biomarkers for the Risk Stratification of High-Grade Gliomas. Yang G; Sha Y; Wang X; Tan Y; Zhang H Contrast Media Mol Imaging; 2022; 2022():8952357. PubMed ID: 35386727 [TBL] [Abstract][Full Text] [Related]
15. A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. Chai RC; Chang YZ; Wang QW; Zhang KN; Li JJ; Huang H; Wu F; Liu YQ; Wang YZ Front Genet; 2019; 10():910. PubMed ID: 31611911 [TBL] [Abstract][Full Text] [Related]
16. Multiparametric Radiogenomic Model to Predict Survival in Patients with Glioblastoma. Mahmoudi K; Kim DH; Tavakkol E; Kihira S; Bauer A; Tsankova N; Khan F; Hormigo A; Yedavalli V; Nael K Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339340 [TBL] [Abstract][Full Text] [Related]
17. Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI. Sha Y; Yan Q; Tan Y; Wang X; Zhang H; Yang G Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900232 [TBL] [Abstract][Full Text] [Related]
18. Development and Validation of a MRI-Based Radiomics Prognostic Classifier in Patients with Primary Glioblastoma Multiforme. Chen X; Fang M; Dong D; Liu L; Xu X; Wei X; Jiang X; Qin L; Liu Z Acad Radiol; 2019 Oct; 26(10):1292-1300. PubMed ID: 30660472 [TBL] [Abstract][Full Text] [Related]
19. Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. Kickingereder P; Neuberger U; Bonekamp D; Piechotta PL; Götz M; Wick A; Sill M; Kratz A; Shinohara RT; Jones DTW; Radbruch A; Muschelli J; Unterberg A; Debus J; Schlemmer HP; Herold-Mende C; Pfister S; von Deimling A; Wick W; Capper D; Maier-Hein KH; Bendszus M Neuro Oncol; 2018 May; 20(6):848-857. PubMed ID: 29036412 [TBL] [Abstract][Full Text] [Related]
20. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter. Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]